L-P Ge1, J Li, Q-L Bao, P Chen, Q Jiang, L-R Zhu. 1. Department of Pulmonary Medicine, Affiliated Hospital of Jiangsu University, 438 North Jiefang Street, Zhenjiang, 212001, China.
Abstract
PURPOSE: Previous studies have demonstrated that plasma D-dimer, a degradation product of cross-linked fibrin, correlated with tumor stage and prognosis in cancer patients. The aim of this study is to examine whether plasma D-dimer levels before and during chemotherapy predict tumor response and survival in advanced NSCLC patients undergoing first line chemotherapy. METHODS: Plasma D-dimer levels before (B0), and after one (B1) and two (B2) cycles of chemotherapy in 82 patients with advanced NSCLC were measured and correlated with treatment response, clinical features, progression-free survival (PFS) and overall survival. RESULTS: A significant correlation was identified between changes in D-dimer levels before and after two chemotherapy cycles and treatment response. In addition, there were significant correlations between D-dimer positivity at B0, B1 and B2 time points and tumor stage, number of metastatic sites and treatment response. Patients with positivity of D-dimer at B0, B1 and B2 had significantly shorter PFS compared with those with negativity. Notably, positivity of D-dimer at B1 and B2 time points was an independent predictive factor for unfavorable PFS. CONCLUSIONS: The positivity of D-dimer before and during chemotherapy is a predictor of treatment response and worse PFS in patients with advanced NSCLC. D-dimer levels provide prognostic information in addition to that of imaging studies.
PURPOSE: Previous studies have demonstrated that plasma D-dimer, a degradation product of cross-linked fibrin, correlated with tumor stage and prognosis in cancerpatients. The aim of this study is to examine whether plasma D-dimer levels before and during chemotherapy predict tumor response and survival in advanced NSCLCpatients undergoing first line chemotherapy. METHODS: Plasma D-dimer levels before (B0), and after one (B1) and two (B2) cycles of chemotherapy in 82 patients with advanced NSCLC were measured and correlated with treatment response, clinical features, progression-free survival (PFS) and overall survival. RESULTS: A significant correlation was identified between changes in D-dimer levels before and after two chemotherapy cycles and treatment response. In addition, there were significant correlations between D-dimer positivity at B0, B1 and B2 time points and tumor stage, number of metastatic sites and treatment response. Patients with positivity of D-dimer at B0, B1 and B2 had significantly shorter PFS compared with those with negativity. Notably, positivity of D-dimer at B1 and B2 time points was an independent predictive factor for unfavorable PFS. CONCLUSIONS: The positivity of D-dimer before and during chemotherapy is a predictor of treatment response and worse PFS in patients with advanced NSCLC. D-dimer levels provide prognostic information in addition to that of imaging studies.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Joseph D Khoury; Dorothy M Adcock; Fanny Chan; James T Symanowski; Stefan Tiefenbacher; Oscar Goodman; Lazara Paz; Yupo Ma; David C Ward; Nicholas J Vogelzang; Louis M Fink Journal: Am J Clin Pathol Date: 2010-12 Impact factor: 2.493
Authors: Mark A Socinski; Richard Crowell; Thomas E Hensing; Corey J Langer; Rogerio Lilenbaum; Alan B Sandler; David Morris Journal: Chest Date: 2007-09 Impact factor: 9.410
Authors: G Altiay; A Ciftci; M Demir; Z Kocak; N Sut; E Tabakoglu; O N Hatipoglu; T Caglar Journal: Clin Oncol (R Coll Radiol) Date: 2007-05-21 Impact factor: 4.126
Authors: Lili Ge; Guangquan Liu; Kai Hu; Ke Huang; Mi Zhang; Juan Zhou; Fang Teng; Jian Cao; Chencheng Dai; Xuemei Jia Journal: Technol Cancer Res Treat Date: 2020 Jan-Dec